Pyridine → (3S,4R)-1-(t-butyldimethylsilyl)3-[(R)-1-(t-butyldimethylsilyloxy)ethyl]-4-[3-(4-nitrobenzyl)oxycarbonyl-2-oxopropyl]azetidin-2-one

HRID 435087ノート

反応式

HRID 435087 の反応式
N1C=CC=CC=1.[Si:7]([N:14]1[C@H:17]([CH2:18][CH:19]([OH:34])[CH2:20][C:21]([O:23][CH2:24][C:25]2[CH:30]=[CH:29][C:28]([N+:31]([O-:33])=[O:32])=[CH:27][CH:26]=2)=[O:22])[C@@H:16]([C@H:35]([O:37][Si:38]([C:41]([CH3:44])([CH3:43])[CH3:42])([CH3:40])[CH3:39])[CH3:36])[C:15]1=[O:45])([C:10]([CH3:13])([CH3:12])[CH3:11])([CH3:9])[CH3:8]>C(Cl)Cl.[O-2].[O-2].[O-2].[Cr+6]>[Si:7]([N:14]1[C@H:17]([CH2:18][C:19](=[O:34])[CH2:20][C:21]([O:23][CH2:24][C:25]2[CH:30]=[CH:29][C:28]([N+:31]([O-:33])=[O:32])=[CH:27][CH:26]=2)=[O:22])[C@@H:16]([C@H:35]([O:37][Si:38]([C:41]([CH3:44])([CH3:43])[CH3:42])([CH3:39])[CH3:40])[CH3:36])[C:15]1=[O:45])([C:10]([CH3:12])([CH3:11])[CH3:13])([CH3:9])[CH3:8]

参加物

5

反応物 2

HCID 1049PyridineHCID 13104637(3S,4R)-1-(t-butyldimethylsilyl)-3-[(R)-1-(t-butyldimethylsilyloxy)ethyl]-4-[3-(4-nitrobenzyl)oxycarbonyl-2-hydroxypropyl]azetidin-2-one

生成物 1

HCID 13018175(3S,4R)-1-(t-butyldimethylsilyl)3-[(R)-1-(t-butyldimethylsilyloxy)ethyl]-4-[3-(4-nitrobenzyl)oxycarbonyl-2-oxopropyl]azetidin-2-one

試薬・触媒・溶媒 2

HCID 10219390chromium (VI) trioxide触媒HCID 6344Dichloromethane溶媒2 回

実験手順

Anhydrous chromium trioxide (10.0 mmol) is added to a soution of anhydrous pyridine (20.0 mmol) in 30 ml of anhydrous methylene chloride. After stirring at room temperature for 15 min., the reaction mixture is treated all at once with a solution of (3S,4R)-1-(t-butyldimethylsilyl)-3-[(R)-1-(t-butyldimethylsilyloxy)ethyl]-4-[3-(4-nitrobenzyl)oxycarbonyl-2-hydroxypropyl]-azetidin-2-one (1.00 mmol) in anhydrous methylene chloride (8 ml). The resulting mixture is stirred at room temperature for 5 min. The CH2Cl2 layer is decanted from the dark, tarry residue which is triturated with more CH2Cl2. The combined CH2Cl2 phase is concentrated in vacuo. The residue is triturated with ether (100 ml) and the ether extracts are filtered. The filtrate is washed with 5% aqueous sodium bicarbonate solution, 2.5 N HCl, 5% NaHCO3 and brine, dried over magnesium sulfate and concentrated in vacuo to yield (3S,4R)-1-(t-butyldimethylsilyl)-3-[(R)-1 -(t-butyldimethylsilyloxy)ethyl]-4-[3-(4-nitrobenzyl)oxycarbonyl-2-oxopropyl]azetidin-2-one. n.m.r. (CDCl3) δ7.85 (2d-aromatic, 4), δ5.27 (s,2), δ4.05 (m,2), δ3.6 (s,2), δ2.4-3.2 (dd overlapping ABq,3), δ1.2 (d,3,J=6.6), δ0.9 (2s,18), δ0.22 (s,6), δ0.05 (s,6).

後処理

  1. stirringThe resulting mixture is stirred at room temperature for 5 min
  2. customThe CH2Cl2 layer is decanted from the dark, tarry residue which
  3. customis triturated with more CH2Cl2
  4. concentrationThe combined CH2Cl2 phase is concentrated in vacuo
  5. customThe residue is triturated with ether (100 ml)
  6. filtrationthe ether extracts are filtered
  7. washThe filtrate is washed with 5% aqueous sodium bicarbonate solution, 2.5 N HCl, 5% NaHCO3 and brine
  8. dry with materialdried over magnesium sulfate
  9. concentrationconcentrated in vacuo

出典と根拠

ORDレコード
ord-54d08feb5f0f46c29f5c273bd709c747
出典データセット
uspto-grants-1983_08
特許番号
US04400323

反応ノート

読み込み中…